The weekly litigation news digest is live. Subscribe now

IP Verse

Deuterated Derivatives Of Ruxolitinib - EP3450434

The patent EP3450434 was granted to Concert Pharmaceuticals on Feb 24, 2021. The application was filed on Jun 14, 2013 under application number EP18188152A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3450434

CONCERT PHARMACEUTICALS
Application Number
EP18188152A
Filing Date
Jun 14, 2013
Status
Granted And Under Opposition
Jan 22, 2021
Publication Date
Feb 24, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
INCYTENov 23, 2021CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2006079502
DESCRIPTIONUS2006094744
DESCRIPTIONUS2008312258
DESCRIPTIONUS5304121
DESCRIPTIONUS5886026
DESCRIPTIONUS6099562
DESCRIPTIONUS6803031
DESCRIPTIONUS7014866
DESCRIPTIONUS7598257
DESCRIPTIONWO2010083283
EXAMINATIONWO2014078486
OPPOSITIONUS2007135461
OPPOSITIONUS7855204
OPPOSITIONWO2013188783
SEARCHUS2007135461

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents